Production (Stage)
NuGen Medical Devices Inc.
NGMD.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 131.25% | 139.52% | 351.80% | -35.12% | 95.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 131.25% | 139.52% | 351.80% | -35.12% | 95.56% |
| Cost of Revenue | 133.33% | 73.41% | 525.24% | -42.47% | 194.34% |
| Gross Profit | 130.77% | 254.75% | 250.46% | -28.72% | 53.54% |
| SG&A Expenses | -47.56% | -56.85% | 10.56% | -73.22% | -11.19% |
| Depreciation & Amortization | -14.08% | 0.71% | -14.35% | -12.18% | -4.48% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.30% | -47.25% | 18.44% | -67.88% | -9.61% |
| Operating Income | 46.83% | 61.60% | -0.04% | 68.24% | 11.13% |
| Income Before Tax | 180.73% | 119.31% | -27.04% | 60.89% | 13.20% |
| Income Tax Expenses | -- | -114.97% | 1,480.00% | -- | -- |
| Earnings from Continuing Operations | 180.53% | 119.26% | -27.46% | 61.01% | 13.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 180.53% | 119.26% | -27.46% | 61.01% | 13.20% |
| EBIT | 46.83% | 61.60% | -0.04% | 68.24% | 11.13% |
| EBITDA | 51.84% | 67.50% | -1.38% | 72.75% | 12.35% |
| EPS Basic | 172.73% | 117.89% | -8.70% | 70.64% | 48.44% |
| Normalized Basic EPS | 173.17% | 76.27% | -3.33% | 53.73% | 48.75% |
| EPS Diluted | 172.73% | 117.89% | -8.70% | 70.64% | 48.44% |
| Normalized Diluted EPS | 173.17% | 76.27% | -3.33% | 53.73% | 48.75% |
| Average Basic Shares Outstanding | 10.48% | 10.21% | 17.73% | 31.52% | 67.85% |
| Average Diluted Shares Outstanding | 10.48% | 10.21% | 17.73% | 31.52% | 67.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |